Joana Goncalves Sells 7,000 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) insider Joana Goncalves sold 7,000 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $111.84, for a total transaction of $782,880.00. Following the completion of the sale, the insider owned 32,718 shares in the company, valued at approximately $3,659,181.12. This trade represents a 17.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Joana Goncalves also recently made the following trade(s):

• On Monday, June 15th, Joana Goncalves sold 7,947 shares of Oruka Therapeutics stock. The stock was sold at an average price of $69.28, for a total value of $550,568.16.

Oruka Therapeutics Stock Performance

Shares of Oruka Therapeutics stock traded up $1.62 during midday trading on Monday, hitting $112.66. The company had a trading volume of 514,852 shares, compared to its average volume of 1,134,557. Oruka Therapeutics, Inc. has a 52-week low of $14.08 and a 52-week high of $113.04. The stock has a market capitalization of $7.46 billion, a P/E ratio of -55.50 and a beta of -0.34. The company has a 50 day moving average of $87.52 and a 200 day moving average of $62.81.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). Equities research analysts forecast that Oruka Therapeutics, Inc. will post -2.27 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on ORKA shares. Wall Street Zen lowered shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday. Piper Sandler reiterated an “overweight” rating and set a $180.00 price target on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. BTIG Research reissued a “buy” rating and set a $151.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Wedbush reaffirmed an “outperform” rating and issued a $165.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Finally, Barclays increased their target price on Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a research note on Monday, April 27th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $134.30.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Artia Global Partners LP bought a new position in Oruka Therapeutics during the second quarter valued at approximately $3,179,000. Bank of America Corp DE purchased a new stake in Oruka Therapeutics during the 2nd quarter valued at $33,578,000. Freestone Grove Partners LP purchased a new stake in Oruka Therapeutics during the 2nd quarter valued at $2,134,000. Jupiter Topco LLC purchased a new stake in Oruka Therapeutics during the 2nd quarter valued at $130,968,000. Finally, J. Goldman & Co LP bought a new position in shares of Oruka Therapeutics during the 2nd quarter valued at $1,176,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.